AAAAAA
Results: 1-25/31
Authors:
Leibovici, D
Zisman, A
Siegel, YI
Lindner, A
Citation: D. Leibovici et al., Cryosurgical ablation for prostate cancer: Preliminary results of a new advanced technique, ISR MED ASS, 3(7), 2001, pp. 484-487
Authors:
Zisman, A
Ng, CP
Pantuck, AJ
Bonavida, B
Belldegrun, AS
Citation: A. Zisman et al., Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis, J IMMUNOTH, 24(6), 2001, pp. 459-471
Authors:
Chao, D
Zisman, A
Freedland, SJ
Pantuck, AJ
Said, JW
Belldegrun, AS
Citation: D. Chao et al., Sarcomatoid renal cell carcinoma: basic biology, clinical behavior and response to therapy, UROL ONCOL, 6(6), 2001, pp. 231-238
Authors:
Wieder, J
Freedland, SJ
Pantuck, AJ
Zisman, A
Belldegrun, AS
Citation: J. Wieder et al., Update on gene and immune based therapy for urologic malignancy, UROL ONCOL, 6(6), 2001, pp. 265-275
Authors:
Belldegrun, A
Tso, CL
Zisman, A
Naitoh, J
Said, J
Pantuck, AJ
Hinkel, A
de Kernion, J
Figlin, R
Citation: A. Belldegrun et al., Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial andbasic biology, HUM GENE TH, 12(8), 2001, pp. 883-892
Authors:
Pantuck, AJ
Zisman, A
Belldegrun, A
Citation: Aj. Pantuck et al., Gene and immune therapy for renal cell carcinoma, INT J UROL, 8(7), 2001, pp. S1-S4
Authors:
Kleinmann, J
Siegel, Y
Cipele, H
Goren, E
Zisman, A
Leibovici, D
Lindner, A
Citation: J. Kleinmann et al., Factors affecting tube dwelling time after percutaneous nephrolithotomy, J ENDOUROL, 15(8), 2001, pp. 793-795
Authors:
Zisman, A
Pantuck, AJ
Dorey, F
Said, JW
Shvarts, O
Quintana, D
Gitlitz, BJ
deKernion, JB
Figlin, RA
Belldegrun, AS
Citation: A. Zisman et al., Improved prognostication of renal cell carcinoma using an integrated staging system, J CL ONCOL, 19(6), 2001, pp. 1649-1657
Authors:
Zisman, A
Pantuck, AJ
Figlin, RA
Belldegrun, AS
Citation: A. Zisman et al., Validation of the UCLA integrated staging system for patients with renal cell carcinoma, J CL ONCOL, 19(17), 2001, pp. 3792-3793
Authors:
Pantuck, AJ
Zisman, A
Henderson, D
Wilson, D
Schreiber, A
Belldegrun, A
Citation: Aj. Pantuck et al., New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions, UROLOGY, 57(4A), 2001, pp. 95-99
Authors:
Zisman, A
Leibovici, D
Kleinmann, J
Cooper, A
Siegel, Y
Lindner, A
Citation: A. Zisman et al., The impact of prostate biopsy on patient well-being: A prospective study of voiding impairment, J UROL, 166(6), 2001, pp. 2242-2246
Authors:
Pantuck, AJ
Zisman, A
Belldegrun, AS
Citation: Aj. Pantuck et al., The changing natural history of renal cell carcinoma, J UROL, 166(5), 2001, pp. 1611-1623
Authors:
Zisman, A
Pantuck, AJ
Chao, D
Dorey, F
Said, JW
Gitlitz, BJ
de Kernion, JB
Figlin, RA
Belldegrun, AS
Citation: A. Zisman et al., Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. Better correlates with clinicaloutcome, J UROL, 166(1), 2001, pp. 54-58
Authors:
Zisman, A
Leibovici, D
Kleinmann, J
Siegel, YI
Lindner, A
Citation: A. Zisman et al., The impact of prostate biopsy on patient well-being: A prospective study of pain, anxiety and erectile dysfunction, J UROL, 165(2), 2001, pp. 445-454
Authors:
Kim, JK
Zisman, A
Fillmore, JJ
Peroni, OD
Kotani, K
Perret, P
Zong, HH
Dong, JY
Kahn, CR
Kahn, BB
Shulman, GI
Citation: Jk. Kim et al., Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4, J CLIN INV, 108(1), 2001, pp. 153-160
Authors:
Tso, CL
Zisman, A
Pantuck, A
Calilliw, R
Hernandez, JM
Paik, S
Nguyen, D
Gitlitz, B
Shintaku, PI
de Kernion, S
Figlin, R
Belldegrun, A
Citation: Cl. Tso et al., Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 andGranulocyte/Monocyte-Colony stimulating factor, CANCER RES, 61(21), 2001, pp. 7925-7933
Authors:
Zisman, A
Pantuck, AJ
Belldegrun, A
Citation: A. Zisman et al., Gene and immune-based therapies for genitourinary malignancies: Current status and future prospects, ISR MED ASS, 2(1), 2000, pp. 33-42
Authors:
Zisman, A
Peroni, OD
Abel, ED
Michael, MD
Mauvais-Jarvis, F
Lowell, BB
Wojtaszewski, JFP
Hirshman, MF
Virkamaki, A
Goodyear, LJ
Kahn, CR
Kahn, BB
Citation: A. Zisman et al., Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance, NAT MED, 6(8), 2000, pp. 924-928
Authors:
Zisman, A
Citation: A. Zisman, An overview of XML, COMP CON EN, 11(4), 2000, pp. 165-167
Authors:
Delaney, ME
Zisman, A
Kettyle, WM
Citation: Me. Delaney et al., Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome, END METAB C, 29(4), 2000, pp. 683
Authors:
Pantuck, AJ
Zisman, A
Belldegrun, AS
Citation: Aj. Pantuck et al., Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions, WORLD J URO, 18(2), 2000, pp. 143-147
Authors:
Pantuck, AJ
Zisman, A
Rauch, MK
Belldegrun, A
Citation: Aj. Pantuck et al., Incidental renal tumors, UROLOGY, 56(2), 2000, pp. 190-196
Authors:
Nentwich, C
Emmerich, W
Finkelstein, A
Zisman, A
Citation: C. Nentwich et al., BOX: Browsing objects in XML, SOFTW PR EX, 30(15), 2000, pp. 1661-1676
Authors:
Leibovici, D
Zisman, A
Chen-Levyi, Z
Cypele, H
Siegel, YI
Faitelovich, S
Lindner, A
Citation: D. Leibovici et al., Elevated prostate specific antigen serum levels after intravesical instillation of bacillus Calmette-Guerin, J UROL, 164(5), 2000, pp. 1546-1549
Authors:
Patel, BJ
Pantuck, AJ
Zisman, A
Tsui, KH
Paik, SH
Caliliw, R
Sheriff, S
Wu, L
deKernion, JB
Tso, CL
Belldegrun, AS
Citation: Bj. Patel et al., CL1-GFP: An androgen independent metastatic tumor model for prostate cancer, J UROL, 164(4), 2000, pp. 1420-1425